Abstract
Using a new rabbit model of methicillin-susceptible Staphylococcus aureus knee prosthesis infection, we compared the efficacies of sparfloxacin (50 mg/kg of body weight subcutaneously, twice a day) and pefloxacin (50 mg/kg subcutaneously, twice a day). A partial knee replacement was performed with a silicone implant fitted into the intramedullary canal of the tibia, and 5 x 10(7) CFU of methicillin-susceptible S. aureus was injected into the knee. The 7-day treatment regimen was started 15 days later. The MICs and MBCs of sparfloxacin and pefloxacin were, respectively, 0.06 and 0.25 microgram/ml (MIC) and 0.25 and 1 microgram/ml (MBC). The peak levels of sparfloxacin and pefloxacin in serum were 3.6 and 21 micrograms/ml, respectively. Three weeks after the end of treatment, animals were sacrificed and tibias were removed, pulverized, and quantitatively cultured. In contrast to pefloxacin (3.61 +/- 1.64 log10 CFU/g of bone), sparfloxacin significantly reduced the bacterial density (2.12 +/- 1.1 log10 CFU/g of bone) (P = 0.01) in comparison with the level in controls (4.59 +/- 1.21 log10 CFU/g of bone), without selection of resistant variants. Sparfloxacin was significantly more effective than pefloxacin (P = 0.025). The autoradiographic pattern of [14C]sparfloxacin diffusion was studied in noninfected animals with prostheses and in infected animals 15 days after inoculation. Sixty minutes after completion of infusion of 250 microCi of [14C]sparfloxacin, in infected animals the highest levels of radioactivity were detected around the prosthesis, in femoral cartilage, and in articular ligaments. Radioactivity was slightly less intense in bone marrow and muscles and was very weak in compact bone. The distribution of sparfloxacin in uninfected rabbits was similar. Thus, sparfloxacin may represent a valid alternative therapy in these infections provided that it is carefully monitored for potential side effects.
Full Text
The Full Text of this article is available as a PDF (606.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Belmatoug N., Crémieux A. C., Bleton R., Volk A., Saleh-Mghir A., Grossin M., Garry L., Carbon C. A new model of experimental prosthetic joint infection due to methicillin-resistant Staphylococcus aureus: a microbiologic, histopathologic, and magnetic resonance imaging characterization. J Infect Dis. 1996 Aug;174(2):414–417. doi: 10.1093/infdis/174.2.414. [DOI] [PubMed] [Google Scholar]
- Bouissou H., Caujolle D., Caujolle F., Milhaud G. Tissus cartilagineux et acide nalidixique. C R Acad Sci Hebd Seances Acad Sci D. 1978 Jun 12;286(23):1743–1746. [PubMed] [Google Scholar]
- Costerton J. W. The etiology and persistence of cryptic bacterial infections: a hypothesis. Rev Infect Dis. 1984 Sep-Oct;6 (Suppl 3):S608–S616. doi: 10.1093/clinids/6.supplement_3.s608. [DOI] [PubMed] [Google Scholar]
- Cremieux A. C., Maziere B., Vallois J. M., Ottaviani M., Azancot A., Raffoul H., Bouvet A., Pocidalo J. J., Carbon C. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis. 1989 May;159(5):938–944. doi: 10.1093/infdis/159.5.938. [DOI] [PubMed] [Google Scholar]
- Cremieux A. C., Saleh-Mghir A., Vallois J. M., Maziere B., Muffat-Joly M., Devine C., Bouvet A., Pocidalo J. J., Carbon C. Efficacy of temafloxacin in experimental Streptococcus adjacens endocarditis and autoradiographic diffusion pattern of [14C]temafloxacin in cardiac vegetations. Antimicrob Agents Chemother. 1992 Oct;36(10):2216–2221. doi: 10.1128/aac.36.10.2216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dellamonica P., Etesse-Carsenti H., Bernard E., Mondain V., Durant J., Argenson C. Pefloxacin in the treatment of bone infections associated with foreign material. J Antimicrob Chemother. 1990 Oct;26 (Suppl B):199–205. doi: 10.1093/jac/26.suppl_b.199. [DOI] [PubMed] [Google Scholar]
- Drancourt M., Stein A., Argenson J. N., Zannier A., Curvale G., Raoult D. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother. 1993 Jun;37(6):1214–1218. doi: 10.1128/aac.37.6.1214. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Drusano G. L., Johnson D. E., Rosen M., Standiford H. C. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993 Mar;37(3):483–490. doi: 10.1128/aac.37.3.483. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dworkin R., Modin G., Kunz S., Rich R., Zak O., Sande M. Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. Antimicrob Agents Chemother. 1990 Jun;34(6):1014–1016. doi: 10.1128/aac.34.6.1014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fischman A. J., Livni E., Babich J., Alpert N. M., Liu Y. Y., Thom E., Cleeland R., Prosser B. L., Callahan R. J., Correia J. A. Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography. Antimicrob Agents Chemother. 1992 Oct;36(10):2286–2292. doi: 10.1128/aac.36.10.2286. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fischman A. J., Livni E., Babich J., Alpert N. M., Liu Y. Y., Thom E., Cleeland R., Prosser B. L., Correia J. A., Strauss H. W. Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. Antimicrob Agents Chemother. 1993 Oct;37(10):2144–2152. doi: 10.1128/aac.37.10.2144. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fitzgerald R. H., Jr Infections of hip prostheses and artificial joints. Infect Dis Clin North Am. 1989 Jun;3(2):329–338. [PubMed] [Google Scholar]
- Gentry L. O. Oral antimicrobial therapy for osteomyelitis. Ann Intern Med. 1991 Jun 1;114(11):986–987. doi: 10.7326/0003-4819-114-11-986. [DOI] [PubMed] [Google Scholar]
- Gentry L. O., Rodriguez-Gomez G. Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrob Agents Chemother. 1991 Mar;35(3):538–541. doi: 10.1128/aac.35.3.538. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gentry L. O., Rodriguez G. G. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother. 1990 Jan;34(1):40–43. doi: 10.1128/aac.34.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Henry N. K., Rouse M. S., Whitesell A. L., McConnell M. E., Wilson W. R. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med. 1987 Apr 27;82(4A):73–75. [PubMed] [Google Scholar]
- Mader J. T., Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother. 1989 May;33(5):689–692. doi: 10.1128/aac.33.5.689. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mader J. T., Cantrell J. S., Calhoun J. Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. J Bone Joint Surg Am. 1990 Jan;72(1):104–110. [PubMed] [Google Scholar]
- Norden C. W. Lessons learned from animal models of osteomyelitis. Rev Infect Dis. 1988 Jan-Feb;10(1):103–110. doi: 10.1093/clinids/10.1.103. [DOI] [PubMed] [Google Scholar]
- Norden C., Nelson J. D., Mader J. T., Calandra G. B. Evaluation of new anti-infective drugs for the treatment of infections of prosthetic hip joints. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992 Nov;15 (Suppl 1):S177–S181. doi: 10.1093/clind/15.supplement_1.s177. [DOI] [PubMed] [Google Scholar]
- Widmer A. F., Frei R., Rajacic Z., Zimmerli W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis. 1990 Jul;162(1):96–102. doi: 10.1093/infdis/162.1.96. [DOI] [PubMed] [Google Scholar]
- Widmer A. F., Gaechter A., Ochsner P. E., Zimmerli W. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis. 1992 Jun;14(6):1251–1253. doi: 10.1093/clinids/14.6.1251. [DOI] [PubMed] [Google Scholar]
- Zimmerli W., Frei R., Widmer A. F., Rajacic Z. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother. 1994 May;33(5):959–967. doi: 10.1093/jac/33.5.959. [DOI] [PubMed] [Google Scholar]